“Liver Cirrhosis Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Liver Cirrhosis Market.
The Liver Cirrhosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Liver Cirrhosis Pipeline Report:
Companies across the globe are diligently working toward developing novel Liver Cirrhosis treatment therapies with a considerable amount of success over the years.
Liver Cirrhosis companies working in the treatment market are PharmaIN, Gwo Xi Stem Cell Applied Technology Co., Ltd., Lipocine Inc., Calliditas Therapeutics, Galectin Therapeutics, Zydus Therapeutics, CymaBay Therapeutics, and others, are developing therapies for the Liver Cirrhosis treatment
Emerging Liver Cirrhosis therapies in the different phases of clinical trials are- PHIN-214, GXHPC1, LPCN 1148, Setanaxib, Belapectin, Saroglitazar, Seladelpar, and others are expected to have a significant impact on the Liver Cirrhosis market in the coming years.
In January 2025, Akero Therapeutics has announced preliminary topline results from week 96 of its Phase IIb SYMMETRY study evaluating efruxifermin (EFX) in adults with biopsy-confirmed compensated cirrhosis (F4), Child-Pugh Class A, caused by metabolic dysfunction-associated steatohepatitis (MASH). This placebo-controlled, multicenter, double-blind, dose-ranging, randomized trial focused on individuals with the condition.
In December 2024, Galectin Therapeutics revealed findings from its global NAVIGATE clinical trial assessing belapectin in individuals with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal hypertension.
In October 2024, PharmaIN Corporation announced that it will present interim findings from its ongoing Phase I clinical trial of PHIN-214, its leading candidate for preventing and treating decompensated cirrhosis.
In June 2024, Resolution Therapeutics Limited, in collaboration with the University of Edinburgh, presented key data on RTX001 at the EASL Congress 2024 in Milan, Italy, highlighting the promising potential of macrophage cell therapy for treating advanced liver cirrhosis.
In June 2024, Lipocine announced that Phase II findings on LPCN 1148 in cirrhosis were showcased in a late-breaking oral presentation at the EASL Congress 2024 in Milan, Italy.
In April 2024, LyGenesis announced that the first patient has received a dose in their Phase IIa clinical trial assessing their innovative allogenic regenerative cell therapy, transplanted into lymph nodes, as a potential treatment for end-stage liver disease (ESLD).
In March 2024, Lipocine reported positive topline results from a Phase II clinical trial of LPCN 1148, an oral therapy in development for managing liver cirrhosis.
Liver Cirrhosis Overview
Liver cirrhosis is a late stage of scarring (fibrosis) of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcoholism. The liver carries out several necessary functions, including detoxifying harmful substances in your body, cleaning your blood, and making vital nutrients. Cirrhosis can lead to a number of complications, including liver cancer.
Get a Free Sample PDF Report to know more about Liver Cirrhosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/liver-cirrhosis-pipeline-insight
Emerging Liver Cirrhosis Drugs Under Different Phases of Clinical Development Include:
PHIN-214: PharmaIN
GXHPC1: Gwo Xi Stem Cell Applied Technology Co., Ltd.
LPCN 1148: Lipocine Inc.
Setanaxib: Calliditas Therapeutics
Belapectin: Galectin Therapeutics
Saroglitazar: Zydus Therapeutics
Seladelpar: CymaBay Therapeutics
Liver Cirrhosis Route of Administration
Liver Cirrhosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous
Liver Cirrhosis Molecule Type
Liver Cirrhosis Products have been categorized under various Molecule types, such as
Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine
Liver Cirrhosis Pipeline Therapeutics Assessment
Liver Cirrhosis Assessment by Product Type
Liver Cirrhosis By Stage and Product Type
Liver Cirrhosis Assessment by Route of Administration
Liver Cirrhosis By Stage and Route of Administration
Liver Cirrhosis Assessment by Molecule Type
Liver Cirrhosis by Stage and Molecule Type
DelveInsight’s Liver Cirrhosis Report covers around 50+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Liver Cirrhosis product details are provided in the report. Download the Liver Cirrhosis pipeline report to learn more about the emerging Liver Cirrhosis therapies
Some of the key companies in the Liver Cirrhosis Therapeutics Market include:
Key companies developing therapies for Liver Cirrhosis are – Astrazeneca, Bayer, Sanofi, Pfizer, Merck & Co., Novartis, Hoffmann-La Roche, Takeda, Gilead Sciences, Shionogi Inc., Promethera, and others.
Liver Cirrhosis Pipeline Analysis:
The Liver Cirrhosis pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Liver Cirrhosis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Liver Cirrhosis Treatment.
Liver Cirrhosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Liver Cirrhosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Liver Cirrhosis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Liver Cirrhosis drugs and therapies
Liver Cirrhosis Pipeline Market Drivers
Increasing Prevalence for the treatment of Liver Cirrhosis, increase in the growing government initiatives and rising awareness are some of the important factors that are fueling the Liver Cirrhosis Market.
Liver Cirrhosis Pipeline Market Barriers
However, side-effects associated with the treatment of Liver Cirrhosis, high cost associated with the treatment and other factors are creating obstacles in the Liver Cirrhosis Market growth.
Scope of Liver Cirrhosis Pipeline Drug Insight
Coverage: Global
Key Liver Cirrhosis Companies: PharmaIN, Gwo Xi Stem Cell Applied Technology Co., Ltd., Lipocine Inc., Calliditas Therapeutics, Galectin Therapeutics, Zydus Therapeutics, CymaBay Therapeutics, and others
Key Liver Cirrhosis Therapies: PHIN-214, GXHPC1, LPCN 1148, Setanaxib, Belapectin, Saroglitazar, Seladelpar, and others
Liver Cirrhosis Therapeutic Assessment: Liver Cirrhosis current marketed and Liver Cirrhosis emerging therapies
Liver Cirrhosis Market Dynamics: Liver Cirrhosis market drivers and Liver Cirrhosis market barriers
Request for Sample PDF Report for Liver Cirrhosis Pipeline Assessment and clinical trials
Table of Contents
1. Liver Cirrhosis Report Introduction
2. Liver Cirrhosis Executive Summary
3. Liver Cirrhosis Overview
4. Liver Cirrhosis- Analytical Perspective In-depth Commercial Assessment
5. Liver Cirrhosis Pipeline Therapeutics
6. Liver Cirrhosis Late Stage Products (Phase II/III)
7. Liver Cirrhosis Mid Stage Products (Phase II)
8. Liver Cirrhosis Early Stage Products (Phase I)
9. Liver Cirrhosis Preclinical Stage Products
10. Liver Cirrhosis Therapeutics Assessment
11. Liver Cirrhosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Liver Cirrhosis Key Companies
14. Liver Cirrhosis Key Products
15. Liver Cirrhosis Unmet Needs
16 . Liver Cirrhosis Market Drivers and Barriers
17. Liver Cirrhosis Future Perspectives and Conclusion
18. Liver Cirrhosis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
